Editor's Note: Green and red arrows refer to intraday stock price movement.
NEW YORK (
CHANGE IN RATINGS
upgraded at Stifel from Hold to Buy. $70 price target. Stock is attractively valued, following a 9% pullback.
Bank of New York
downgraded at Morgan Stanley to Equal-weight, Morgan Stanley said. Consensus estimates appear too high, as interest rates should remain low in the coming quarters.
downgraded at Deutsche from Buy to Hold, Deutsche Bank said. $85 price target. Positive newsflow is fading.
rated new Buy at Jefferies. $125 price target. Company is a premier large-cap play that's leveraged to rising oil prices.
upgraded at Stifel from Hold to Buy, Stifel Nicolaus said. $42 price targt. Marketplace growth is accelerating.
eBay estimates were boosted through 2012 at UBS. Company is seeing better Marketplace growth. Buy rating and target upped to $40 price target.
upgraded at Citi to Buy from Hold. North American inventory leaner, new merchandising initiatives planned, Citigroup said. Price target increased to $50 from $46.
estimates, target raised at Goldman. Shares of GLW now seen reaching $25, according to Goldman Sachs. Estimates also increased, to match the company's new guidance. Neutral rating.
upgraded at Credit Suisse to Outperform from Neutral. Australia and Ghana are potential game changers, Credit Suisse said. Price target increased to $115 from $105.
downgraded at Wunderlich from Hold to Sell, Wunderlich Securities said. $44 price target. Sales growth appears to have peaked.
upgraded at Stifel from Hold to Buy, Stifel Nicolaus said. $13 price target. Company appears to be at an inflection point.
downgraded at Benchmark from Buy to Hold, Benchmark Company said. $37 price target. National Media trend remain soft.
downgraded at Goldman from Buy to Neutral, Goldman Sachs said. Industry dayrates could remain depressed into 2012.
National Oilwell Varco
upgraded at Citi to Buy from Hold on big order ramp, PS&S profit rebound, Citigroup said. Price target increased to $92 from $78.
downgraded at Benchmark from Hold to Sell, Benchmark Company said. $56 price target. Company is investing more to boost sales growth.
upgraded at Goldman from Sell to Neutral, Goldman Sachs said. $35 price target. Margins can continue to expand in the coming quarters.
downgraded at Piper from Overweight to Neutral, Piper Jaffray said. Valuation call, based on a $106 price target.
upgraded at Goldman from Sell to Neutral, Goldman Sachs said. $28 price target. Company remains leveraged to the current industry cycle.
upgraded at Duncan-Williams from Reduce to Strong Buy, Duncan-Williams said. $93 price target. Valuation call, as the stock is trading near book value and at a discount to its peers.
upgraded at Benchmark from Hold to Buy, Benchmark Company said. Valuation call, based on a $44 price target.
upgraded at Morgan Stanley from Equal-weight to Overweight, Morgan Stanley said. $70 price target. Company should continue to gain market share.
downgraded at Baird from Outperform to Neutral, Robert Baird said. Valuation call, based on a $95 price target.
downgraded at William Blair to Market Perform, William Blair said. Sales trends remain soft.
downgraded at Wells from Outperform to Market Perform, Wells Fargo said. Company lacks near-term catalysts.
Watson Pharmaceuticals numbers increased at Morgan Stanley. WPI estimates were raised through 2013, Morgan Stanley said. Company has improved margin visibility. Overweight rating and new $68 price target.
End of report.
This article was written by a staff member of TheStreet.